Montelukast Ranbaxy

Montelukast, the active ingredient in Montelukast Ranbaxy, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults, adolescents and children as part of a comprehensive asthma treatment plan.

GNH USA supplies Montelukast Ranbaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to treat conditions mediated by leukotrienes, primarily within the respiratory and allergic disease spectrum.

Asthma: improves control of symptoms and reduces the frequency of exacerbations. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity. Allergic rhinitis: alleviates nasal congestion, sneezing and itching.

Montelukast may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Mood changes including depression or suicidal thoughts - Elevated liver enzymes or hepatic injury - Neutropenia or other blood dyscrasias - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe bronchospasm despite therapy

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

Assess hepatic function: monitor liver enzymes in patients with known liver disease. Review psychiatric history: observe for mood alterations or depressive symptoms. Evaluate renal function: adjust use in severe renal impairment. Avoid use in patients with known hypersensitivity to Montelukast or any excipients. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of Montelukast. - Rifampin: enzyme induction can lower drug effectiveness. - Ketoconazole: may increase Montelukast levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Beta‑agonists: additive bronchodilation may require response assessment. - Selective serotonin reuptake inhibitors (SSRIs): possible increased risk of mood changes.